Home›Insulin Glargine And Lixisenatide

Insulin Glargine And Lixisenatide

Also known as: Soliqua 100/33

Insulin AnalogGLP-1 Receptor AgonistGlucagon-like Peptide-1 (GLP-1) Agonists

Route: Subcutaneous

Check Insulin Glargine And Lixisenatide Interactions →

38 interactions on record

Insulin Glargine And Lixisenatide has 38 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Acetaminophen, Albuterol, Alcohol. Patients taking Insulin Glargine And Lixisenatide should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 38
Moderate: 36

Moderate (36)

Insulin Glargine And Lixisenatide + Acetaminophen— Lixisenatide delays gastric emptying which may impact absorption. Should be taken at least 1 hour prior to or 11 hours a…
Insulin Glargine And Lixisenatide + Albuterol— Sympathomimetic agent that may decrease the blood glucose lowering effect. Dose increases and increased glucose monitori…
Insulin Glargine And Lixisenatide + Alcohol— May increase or decrease the blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be requ…
Insulin Glargine And Lixisenatide + Angiotensin Ii— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Clonidine— May increase or decrease blood glucose lowering effect and may blunt signs/symptoms of hypoglycemia. Dose adjustment and…
Insulin Glargine And Lixisenatide + Clozapine— Atypical antipsychotic that may decrease the blood glucose lowering effect. Dose increases and increased glucose monitor…
Insulin Glargine And Lixisenatide + Corticosteroids— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Danazol— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Disopyramide— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Diuretics— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Epinephrine— Sympathomimetic agent that may decrease the blood glucose lowering effect. Dose increases and increased glucose monitori…
Insulin Glargine And Lixisenatide + Estrogens— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Fibrates— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Fluoxetine— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Glucagon— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Guanethidine— May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Isoniazid— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Lithium— May increase or decrease the blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be requ…
Insulin Glargine And Lixisenatide + Macrolide Antibiotics— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Mao Inhibitors— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Monoamine Oxidase Inhibitors (Maois)— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Niacin— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Nonselective Beta-Adrenergic Antagonists— May increase or decrease blood glucose lowering effect and may blunt signs/symptoms of hypoglycemia. Dose adjustment and…
Insulin Glargine And Lixisenatide + Octreotide— Somatostatin analog that may increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monit…
Insulin Glargine And Lixisenatide + Olanzapine— Atypical antipsychotic that may decrease the blood glucose lowering effect. Dose increases and increased glucose monitor…
Insulin Glargine And Lixisenatide + Oral Contraceptives— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required. Should …
Insulin Glargine And Lixisenatide + Pentamidine— May cause hypoglycemia which may sometimes be followed by hyperglycemia. Dose adjustment and increased glucose monitorin…
Insulin Glargine And Lixisenatide + Pentoxifylline— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Phenothiazines— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Pramlintide— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Protease Inhibitors— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Reserpine— May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Salicylates— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Somatropin— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Insulin Glargine And Lixisenatide + Terbutaline— Sympathomimetic agent that may decrease the blood glucose lowering effect. Dose increases and increased glucose monitori…
Insulin Glargine And Lixisenatide + Thyroid Hormones— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Acetaminophen🟡Moderate

Lixisenatide delays gastric emptying which may impact absorption. Should be taken at least 1 hour prior to or 11 hours after SOLIQUA administration.

Insulin Glargine And Lixisenatide + Albuterol🟡Moderate

Sympathomimetic agent that may decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Alcohol🟡Moderate

May increase or decrease the blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Angiotensin Ii🟡Moderate

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Clonidine🟡Moderate

May increase or decrease blood glucose lowering effect and may blunt signs/symptoms of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Clozapine🟡Moderate

Atypical antipsychotic that may decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Corticosteroids🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Danazol🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Disopyramide🟡Moderate

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Diuretics🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Epinephrine🟡Moderate

Sympathomimetic agent that may decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Estrogens🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Fibrates🟡Moderate

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Fluoxetine🟡Moderate

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Glucagon🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Guanethidine🟡Moderate

May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Isoniazid🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Lithium🟡Moderate

May increase or decrease the blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Macrolide Antibiotics🟡Moderate

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Mao Inhibitors🟡Moderate

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Monoamine Oxidase Inhibitors (Maois)🟡Moderate

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Niacin🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Nonselective Beta-Adrenergic Antagonists🟡Moderate

May increase or decrease blood glucose lowering effect and may blunt signs/symptoms of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Octreotide🟡Moderate

Somatostatin analog that may increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Olanzapine🟡Moderate

Atypical antipsychotic that may decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Oral Contraceptives🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required. Should be taken at least 1 hour prior to or 11 hours after SOLIQUA administration.

Insulin Glargine And Lixisenatide + Pentamidine🟡Moderate

May cause hypoglycemia which may sometimes be followed by hyperglycemia. Dose adjustment and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Pentoxifylline🟡Moderate

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Phenothiazines🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Pramlintide🟡Moderate

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Protease Inhibitors🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Reserpine🟡Moderate

May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Salicylates🟡Moderate

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Somatropin🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Terbutaline🟡Moderate

Sympathomimetic agent that may decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Thyroid Hormones🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Insulin Glargine And Lixisenatide + Acetazolamideℹ️Unknown

Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.

Insulin Glargine And Lixisenatide + Somatostatinℹ️Unknown

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.